^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Marginal Zone Lymphoma |
| Drug: | Jaypirca (pirtobrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) - B-Cell Lymphomas
Published date:
04/30/2024
Excerpt:
Preferred regimen...Pirtobrutinib (after prior covalent BTKi)
